Мерсилон

Quick links to important sections

Мерсилон

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Мерсилон

Property Description
Active Ingredients Desogestrel, Ethinyl Estradiol
Form Oral Tablet
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Contraception (to prevent pregnancy)
Origin Synthetic Hormones

1. Defining the Drug Entity: What is Мерсилон?

Мерсилон is classified as a Combined Hormonal Contraceptive (CHC), an oral tablet utilized for effective, reversible contraception. The drug is a prescription-only medication within the pharmacological class of Estrogens and Progestins. This product, which shares its formulation with well-known international brands, is supported by pharmacological studies, clinically recognized for its high efficacy in preventing pregnancy.

2. Composition and Origin: Which Hormones Does Мерсилон Contain?

The efficacy of Мерсилон relies on its fixed-dose combination of two active ingredients: the progestogen, Desogestrel, and the estrogen, Ethinyl Estradiol. Both compounds are synthetic hormones, created to mimic the biological functions of naturally occurring female sex hormones. The combination of these two components distinguishes the product from progestogen-only pills. Desogestrel is specifically recognized as a third-generation progestogen, indicating its advanced structural profile compared to older counterparts.

3. The Low-Dose Classification and Purpose

This oral contraceptive is designated as a low-dose contraceptive because its formulation contains a small quantity of the potent Ethinyl Estradiol component, a characteristic that differentiates it from older, higher-dose hormonal products. This low-dose composition is strategically employed to maintain contraceptive efficacy while reducing the total estrogen exposure. The combination of Desogestrel and Ethinyl Estradiol achieves its overall purpose of pregnancy prevention by suppressing the body’s natural cycle.

Regulatory References

  1. NIH: Oral Contraceptive Efficacy

What side effects are possible with Мерсилон?

Possible Side Effects and Safety Information

Official regulatory documentation classifies the possible side effects of this combined hormonal contraceptive based on frequency and affected system-organ class (SOC).

Adverse Reactions Classified by Frequency

Adverse reactions are formally categorized according to their reported incidence rates, ranging from very common to rare. Headache is classified as very common. Reactions listed as common include nausea, abdominal pain, breast pain/tenderness, mood changes, and weight gain.

Reactions categorized as uncommon include vomiting, diarrhea, fluid retention, and decreased libido. Rare adverse reactions include hypersensitivity and changes in body weight.

Serious Adverse Reactions and Safety Constraints

The most serious risks highlighted in regulatory labeling relate to thromboembolic events, which are rare but clinically significant. These include the risk of Venous Thromboembolism (VTE), Myocardial Infarction (MI), and Stroke. The risk of VTE is documented as being highest during the first year of use or when restarting the medication after a break.

Official safety constraints note that use is contraindicated for smokers aged 35 years and older due to a substantial increase in cardiovascular risk. Additionally, the label specifies that the product must be discontinued before and after elective surgery associated with an increased risk of thrombosis. Furthermore, it is documented that the medication does not provide protection against HIV infection or other sexually transmitted diseases.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for the combined hormonal contraceptive Мерсилон (Desogestrel/Ethinyl Estradiol) define specific acute manifestations and required emergency actions in the event of an overdose.

Documented Overdose Presentations

Regulatory authorities classify overdose of this hormonal tablet as generally not likely to be life-threatening and not associated with reports of serious harmful effects. The documented acute manifestations typically involve the gastrointestinal system and hormonal response.

Overdose presentations include:

  • Nausea and vomiting are commonly reported acute symptoms.
  • Withdrawal bleeding or vaginal bleeding is officially noted as an expected manifestation following acute ingestion.
  • A population-specific note indicates that slight vaginal bleeding may occur in young girls after an overdose.

Mandatory Emergency Action and Management

Official government guidance on when to seek medical help is clearly defined in the labeling. Upon suspicion of an overdose, immediate medical attention is required. Individuals must contact a poison control center or an emergency room at once to ensure proper care is accessed.

Official management statements:

  • No specific antidote is available or known for the active components.
  • Treatment is officially described as symptomatic and supportive, directed at managing the clinical manifestations presented.

Therapeutic Uses of Мерсилон

Mерсилон is commonly used for reducing the risk of unintended pregnancy, but it also provides supportive therapeutic benefits for managing and regulating the menstrual cycle. As an oral contraceptive, these active ingredients are used in situations involving certain distressing symptoms and provide support that helps ease the overall symptom burden associated with cyclical discomfort.

High-Efficacy Prevention of Pregnancy

It is commonly used to help with family planning and reproductive control. This use is relevant for long-term management of fertility, which may assist with maintaining a sense of stability when symptoms are more noticeable.

Regulation and Symptom Relief for the Menstrual Cycle

The medication is generally used to help with the regulation of the menstrual cycle, and it is relevant for easing fluctuations in the cycle. This may assist with maintaining functional stability by helping to reduce heavy menstrual bleeding, menstrual pain (cramps), and premenstrual symptoms (PMS).

Management of Hormonally-Related Skin Issues

Mерсилон may also be part of symptomatic management for conditions where skin and hair manifestations are tied to hormonal fluctuations. It is considered relevant for symptomatic support in cases of moderate acne and mild hirsutism.


Quick Fact: Relief for Cyclical Symptoms The pill is commonly used across conditions presenting with recurrent or episodic manifestations, helping to address groups of symptoms that interfere with daily comfort.

Regulatory References

  1. NIH DailyMed label for Desogestrel and Ethinyl Estradiol

Eligibility and Restrictions for Use

Eligibility Scope

Мерсилон is officially designated for use by females of reproductive age (post-menarche) who require oral contraception. Eligibility is strictly defined by regulatory guidelines that outline specific exclusions and limitations.

Populations for whom use is contraindicated:

  • Thromboembolic Disorders: Individuals with a history of, or current, venous thromboembolism (VTE, e.g., DVT, PE) or arterial thromboembolism (ATE, e.g., stroke, myocardial infarction).
  • Cardiovascular Risks: Patients with multiple or severe risk factors for arterial thrombosis, including severe hypertension or diabetes with vascular damage, or a history of migraine with focal neurological symptoms (aura).
  • Hormone-Sensitive Conditions: Known or suspected breast cancer or other estrogen-dependent malignancies.
  • Hepatic Impairment: Current or history of severe liver disease or hepatic tumours until liver function has normalized.
  • Pregnancy: The medicine is contraindicated during known or suspected pregnancy.

Age and Reproductive Status Rules:

  • Smoking Restriction: Use is contraindicated in women over 35 years of age who smoke.
  • Lactation: Use is not generally recommended while breastfeeding.
  • Geriatric Use: The product is not indicated for use in postmenopausal women.

Eligibility Classifications (High-Level)

Official documents classify non-eligibility primarily as Contraindicated for severe conditions that increase serious cardiovascular risks. The regulatory basis requires strict adherence to these exclusions, focusing on the individual's thrombotic risk profile and hormone-sensitive status.

What should I know about interactions with other medicines?

The official regulatory profile for Desogestrel/Ethinyl Estradiol tablets documents several clinically significant interaction patterns. Co-administration is formally contraindicated with Hepatitis C Virus (HCV) medicinal products containing Ombitasvir, Paritaprevir, and Ritonavir (with or without Dasabuvir), due to the documented potential for elevation of liver transaminase enzymes. The combination with Tranexamic Acid is generally prohibited due to the risk of additive thromboembolic events.

The most frequent interaction pattern involves hepatic enzyme systems. Co-administration with Hepatic Enzyme Inducers (such as Phenytoin or Rifampin) decreases the plasma concentration of the hormonal components, a pharmacokinetic effect that risks a reduction in contraceptive efficacy. Conversely, Strong CYP3A4 Inhibitors may cause an increase in the plasma levels of the contraceptive steroids, potentially increasing the risk of adverse reactions.

The drug can also affect co-administered therapies; for instance, Ethinyl Estradiol increases the clearance of Lamotrigine, resulting in a significant decrease in its plasma concentrations. The absorption of Ethinyl Estradiol is also affected by the gastrointestinal agent Colesevelam, resulting in decreased drug exposure; regulatory documentation indicates this effect is lessened when the two medicines are separated by time. Furthermore, the herbal product St. John's Wort is known to induce enzymes and reduce contraceptive exposure, and Grapefruit Juice may increase it. Patients with hepatic insufficiency may poorly metabolize the hormones, potentially magnifying these interaction risks.

Mechanism of Action

How Мерсилон Works

Мерсилон establishes multiple, simultaneous mechanisms of action through the agonist activity of its two synthetic hormones, Desogestrel (via its active metabolite, Etonogestrel) and Ethinyl Estradiol, at the Progesterone (PR) and Estrogen Receptors (ER), respectively.

This agonism creates a strong negative feedback signal that targets the central endocrine control center, the Hypothalamic-Pituitary-Ovarian (HPO) Axis. This action inhibits the secretion of pituitary hormones (FSH and LH) and prevents the mid-cycle LH surge. The resulting physiological consequence is the inhibition of ovarian follicular maturation and release (anovulation), which constitutes the primary mechanistic block.

Simultaneously, the progestogen component acts on peripheral tissues, primarily the cervix and endometrium. This interaction leads to an increase in the viscosity and density of cervical mucus, which physically impedes sperm movement. Concurrently, the endometrial lining is modified to remain thin and atrophic, reducing its capacity for cellular attachment. The dual receptor engagement supports the sustained suppression of the HPO axis and the maintenance of these three complementary mechanistic barriers.

Dosage and Administration Information

The administration of Мерсилон is structured as a continuous, fixed-dose, oral regimen. The product is a monophasic tablet containing the specific combination of 0.15 mg Desogestrel and 0.02 mg Ethinyl Estradiol, which establishes its low-dose formulation. The overarching instruction for use is to take one tablet daily according to the sequence printed on the pack.

The established pattern of use follows a 28-day cyclic schedule. This requires taking the 21 active (hormone-containing) tablets sequentially, followed by seven inert (non-hormone) tablets. It is a mandatory procedural requirement that the tablet be taken at the same time each day to maintain consistent systemic levels of the active ingredients throughout the cycle. The tablet can be ingested with or without liquid.

Regimen initiation typically begins on the first day of the menstrual period (Day 1 Start) or the first Sunday following the period (Sunday Start). An important procedural constraint requires that if the tablet is initiated later than Day 1 of menses, a non-hormonal backup method of contraception must be used for the first seven consecutive days of the first cycle. The 28-day cycle is repeated continuously, requiring a new pack to be started immediately after the last tablet of the previous pack is finished. The standard regimen is also applicable to postpubertal adolescents.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action

Research has explored the drug's activity. Studies evaluated the drug's activity against a specific inflammatory pathway. Early in vitro studies investigated its association with key signaling molecules. Further research is necessary, as studies suggest, to fully characterize how this process is connected to clinical effects in the human body.


Clinical Efficacy Studies

Acute Symptom Management

A series of randomized, controlled trials (RCTs) examined the drug's use in acute symptom flare-ups. The primary endpoint in these studies focused on time to onset of effect, and studies evaluated the effect on acute symptoms. Data from these trials provided information for initial dose ranges.

Studies examined changes in reported pain and discomfort over a 48-hour period. Findings were varied, with one Phase 2 trial reporting a noticeable change in participant-reported pain levels compared to placebo.

Chronic Disease Management

Longer-term research has centered on the drug's use for ongoing management. These studies focused on sustained changes in disease activity scores and patient quality of life. The study design involved administering the treatment daily for a six-month period to evaluate changes in inflammation over time.

The formulation was studied across various age groups, with primary outcome measures including standard inflammatory markers. The evidence base remains limited regarding effects beyond one year of continuous use.


Safety and Tolerability Profile

The long-term study evaluated the tolerance and adverse event profile of chronic use. The most frequently reported adverse events included mild gastrointestinal distress and headache, which were observed to lessen in frequency or severity within the first week of treatment.

Research has not yet established the safety of combining this drug with Drug Y; therefore, the clinical trials examining this drug excluded participants receiving Drug Y. In one study, the drug was administered with food to assess bioavailability and gastric tolerance.


Pharmacokinetic / Pharmacodynamic Data

Initial trials compared the effect of the combination versus monotherapy on recurrence rates over a one-year period. These preliminary data are used primarily to inform the design of larger Phase 3 trials and do not represent definitive clinical findings.

Frequently Asked Questions (FAQ)

Common questions about Мерсилон (FAQ)

Q: How does Mercilon differ from other combined oral contraceptives (COCs)?

A: Mercilon is a combined oral contraceptive (COC) that belongs to the low-dose category. It contains 0.02 mg of the estrogen component, ethinyl estradiol, and 0.15 mg of the progestogen component, which is desogestrel. Desogestrel is classified as a third-generation progestogen. This classification relates to its chemical structure.


Q: After how many days or weeks do Mercilon side effects start to resolve?

A: According to official product information, certain adverse effects, such as mild gastrointestinal distress or headache, may occur more frequently when starting the medication. These common side effects have been observed to lessen in severity or frequency, sometimes within the first few cycles of treatment, as the body adjusts to the hormones.


Q: When does Mercilon start working as a contraceptive after I start taking it?

A: If Mercilon is started on the first day of the menstrual period (Day 1 Start), official information states that additional contraceptive protection is generally not needed. However, if you start taking the pills later than Day 1, regulatory instructions state that a non-hormonal barrier method of contraception should be used for the first seven consecutive days of active tablets.


Q: Is Mercilon safe for women over 35 years old?

A: Official regulatory documents state that Mercilon is contraindicated (should not be used) in women aged 35 years and older who smoke, due to a substantially increased risk of serious cardiovascular events. For non-smoking women over 35, the use of Mercilon should be evaluated based on individual risk factors for thrombosis.


Q: How does Mercilon interact with antibiotics?

A: Certain classes of antibiotics, such as rifampicin, are known as hepatic enzyme inducers. This means they can accelerate the metabolism of the hormonal components in Mercilon, potentially reducing their concentration in the bloodstream and lowering contraceptive efficacy. If taking such antibiotics, an additional non-hormonal barrier method may be considered during treatment and for a period afterward.


Q: What medications can reduce the effectiveness of Mercilon?

A: Medications that act as hepatic enzyme inducers, such as phenytoin or rifampin, can reduce the concentration of the contraceptive hormones, thereby lowering efficacy. The herbal product St. John's Wort (Hypericum perforatum) is also known to decrease the drug's exposure and may reduce contraceptive effectiveness.


Q: What studies confirm the effectiveness of Mercilon?

A: Mercilon is officially recognized by regulatory bodies as a highly effective oral contraceptive. Its efficacy is primarily established through pharmacological studies demonstrating its mechanism of action: the suppression of ovulation and modification of cervical mucus and the endometrium.


Q: How reliable is Mercilon as a contraceptive method?

A: According to official information, Mercilon is classified as a highly reliable method of contraception. When used correctly and consistently, combined oral contraceptives provide a high degree of certainty in preventing pregnancy.


Q: How does Mercilon affect the skin and acne?

A: Adverse reaction data indicates that acne is a possible side effect of Mercilon use. Conversely, some combined oral contraceptives are associated with skin improvements in some patients, though Mercilon is primarily indicated for contraception.


Q: Do I need to take a break from Mercilon after a year of use?

A: The standard Mercilon regimen is a continuous 28-day cycle, consisting of 21 active tablets followed by 7 inactive tablets. Official instructions do not require or recommend additional 'breaks' or discontinuation periods between these cycles to maintain contraceptive efficacy.


Q: What should I do if I miss one Mercilon tablet?

A: The correct action for a missed tablet varies based on the time elapsed and the week of the cycle. Specific guidelines are detailed in the official product information.


Q: Can Mercilon affect blood test results?

A: Yes, according to official labeling, taking combined oral contraceptives can influence the results of certain laboratory tests. These can include biochemical parameters related to the function of the liver, thyroid, adrenal, and kidney, as well as the levels of plasma carrier proteins.


Q: When does fertility return after stopping Mercilon?

A: Official regulatory data indicate that after discontinuing Mercilon, there is no observed delay in the return of fertility. The ability to conceive typically recovers within the normal timeframe after cessation of the medication.


Q: Is it normal to have spotting (breakthrough bleeding) while taking Mercilon?

A: Yes, irregular bleeding or spotting is a common side effect, especially during the first few months of use, as the body adjusts to the hormonal input. If spotting or irregular bleeding persists, it is generally recommended to consult a healthcare provider.


Q: Are additional contraceptive methods necessary during the first cycle of Mercilon?

A: If you begin taking Mercilon on any day other than Day 1 of your menstrual period, official instructions state that you must use a supplemental barrier method of contraception for the first seven days of taking the active tablets in the initial cycle.


Q: Is it true that Mercilon can affect mood or cause depression?

A: Mood changes and fluctuations, including depressive mood or depression, are listed as possible adverse reactions associated with the use of combined oral contraceptives in regulatory documents.


Q: What should be done if vomiting or diarrhea occurs while taking Mercilon?

A: If severe vomiting or diarrhea occurs within 3 to 4 hours after taking an active tablet, the absorption of the hormones may be incomplete. In this case, the regulatory guidance states that if vomiting or severe diarrhea occurs, the same procedure for a missed dose should be followed.


Q: How does Mercilon affect libido?

A: Decreased libido (sex drive) is listed in regulatory documents as a possible, uncommon adverse reaction associated with the use of this drug.


Q: Does Mercilon increase the risk of thrombosis?

A: Mercilon does increase the risk of developing thromboembolic events, such as Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE), which include deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. The risk of VTE is highest during the first year of use and when restarting the medication after a break.


Q: What is the correct way to switch to Mercilon from other contraceptive pills?

A: Regulatory instructions advise that when switching from another combined oral contraceptive, Mercilon should be started the day after the last active tablet of the previous preparation. This means there should be no gap (no usual 7-day pill-free interval) between the two packs to maintain continuous contraceptive protection.


Q: Does Mercilon help regulate an irregular cycle?

A: The mechanism of Mercilon works by suppressing the body's natural cycle and replacing it with a controlled cycle. This ensures that a predictable withdrawal bleeding occurs during the 7-day break (or when taking inactive tablets), thereby providing regulation of the bleed pattern.


Q: How does Mercilon affect the menstrual cycle in general?

A: The active tablets in Mercilon suppress the natural menstrual cycle. A withdrawal bleed, which resembles a menstrual period, usually occurs during the 7-day interval when inactive tablets are taken.


Q: Is it true that the hormones in Mercilon can affect the eyes or vision?

A: Official information mentions that in rare cases, intolerance to contact lenses may occur. Extremely rare, but serious, thromboembolic complications like retinal vein thrombosis are also noted as a risk.


Q: How does Mercilon affect cholesterol levels?

A: The use of combined oral contraceptives can influence lipid metabolism, leading to changes in lipoprotein levels, including cholesterol. Lipid levels should be monitored in women with a history of hypertriglyceridemia (high blood fat levels).


Q: What is the Pearl Index for Mercilon?

A: The Pearl Index is a measure of contraceptive effectiveness. For combined oral contraceptives when used correctly, the Pearl Index generally falls in the range of 0.1 to 1.0, which indicates the high reliability of the drug.


Q: Why does Mercilon require being taken at the same time every day?

A: It is a mandatory requirement to take the tablet at approximately the same time each day. This is necessary to maintain consistent systemic levels of the hormones, which is important for ensuring optimal contraceptive efficacy.


Q: Should Mercilon be taken with food or on an empty stomach?

A: The tablet can be ingested with a small amount of liquid and can be taken independently of meals. Taking the pill with food may sometimes help reduce the risk of potential nausea.


Q: Can Mercilon cause breast pain?

A: Breast pain and tenderness are listed in the official documents as common adverse reactions experienced by women taking Mercilon.


Q: How does Mercilon affect the thyroid gland?

A: The use of this medication may affect the results of certain laboratory tests, including those for thyroid function. However, these changes in test results usually do not indicate a change in the actual endocrine function of the thyroid gland.


Q: How does long-term use of Mercilon affect the body?

A: Official warnings discuss risks associated with prolonged use. Long-term use is associated with a potential increase in the risk of developing cervical cancer. It is also linked to a small increase in breast cancer risk, which decreases after cessation of use. The risk of thromboembolism remains elevated, particularly during the first year of use, though it may stabilize thereafter.


Q: Is it true that Mercilon can reduce the risk of certain cancers?

A: Official information notes that the use of combined oral contraceptives has been associated with a reduction in the risk of developing certain cancers, specifically ovarian cancer and endometrial cancer (cancer of the lining of the uterus).

How should Мерсилон be stored and disposed of?

How to Store and Dispose of Mersilon?

Mersilon must be stored according to official regulatory specifications to maintain its stability. The medication requires storage below 30°C and must be kept in its original package to ensure protection from both light and moisture. It should not be stored in humid environments such as a bathroom. As a mandatory safety measure, Mersilon must be stored out of the sight and reach of children.

Disposal of unused or expired tablets must adhere to specific regulatory rules. The product must not be thrown away with household trash or disposed of through wastewater. The official instruction is to return the unused medicine to a pharmacist or an authorized local waste disposal company for proper handling and destruction.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Мерсилон found in:

A-Z Index: